Outcome MeasureDepression

IDS-C30

Inventory of Depressive Symptomatology – Clinician Rated

7 Papers in Blossom

Outcome Data Across Studies

Reported results for IDS-C30 across 3 studies with quantitative data.

Outcome data across 6 study arm–timepoint observations
SD
A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression
2020Secondary
Six ketamine infusions(experimental)02536.83.9—
A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression
2020Secondary
Single ketamine + midazolam(active_comparator)02939.87.3—
Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: A randomized trial
2025Primary
Treatment Arm(experimental)02935.99.7—
Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: A randomized trial
2025Primary
Control Arm(active_comparator)02728.98.8—
Esketamine nasal spray versus quetiapine XR in adults with treatment-resistant depression: a secondary analysis of the ESCAPE-TRD randomized clinical trial
2025Secondary
Esketamine(experimental)031644.86.7—
Esketamine nasal spray versus quetiapine XR in adults with treatment-resistant depression: a secondary analysis of the ESCAPE-TRD randomized clinical trial
2025Secondary
Quetiapine XR(active_comparator)032045.26.9—

Papers Using IDS-C30

Open Accessindividual

Neuroplastic white matter changes in patients with major depression following lysergic acid diethylamide treatment

This randomised clinical trial (n=61) in people with major depressive disorder compared low-dose LSD (2 × 25 μg) with moderate-to-high-dose LSD (100 μg then 200 μg) and found that the higher-dose group showed white matter changes on brain scans linked with later improvements in depressive symptoms.

Published
Journal
Cell Reports
Authors
Avram, M., Menegaux, A., Müller, F., Zaczek, H., Korda, A., Rogg, H., Becker, A. M., Ley, L., Liechti, M. E., Borgwardt, S.
Open Accessindividual

Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: A randomized trial

This double-blind controlled trial (n=61) found that high-dose LSD-assisted therapy (100μg + 200μg) reduced depression symptoms more than low-dose LSD (25μg + 25μg) in patients with moderate-to-severe major depressive disorder (MDD), with benefits lasting up to 12 weeks and similar side effects between groups.

Published
Journal
Med
Authors
Mu, F., Zaczek, H., Becker, A. M., Auernig, M., Boehlke, C., Liechti, M. E., Ley, L., Borgwardt, S., Santos De Jesus, J., Loh, N., Kohut, J.
Open Accessindividual

Esketamine Monotherapy in Adults With Treatment-Resistant Depression: A Randomized Clinical Trial

In a phase 4, multicentre, double-blind randomised trial in adults with treatment‑resistant depression, intranasal esketamine monotherapy (56 mg and 84 mg) produced significant reductions in MADRS score versus placebo at day 28 (LS mean differences −5.1 and −6.8; effect sizes 0.48 and 0.63) and demonstrated rapid benefit at 24 hours. The tolerability profile was consistent with prior reports, most commonly nausea, dissociation, dizziness and headache.

Published
Journal
JAMA Psychiatry
Authors
Janik, A., Qiu, X., Lane, R., Popova, V., Drevets, W. C., Canuso, C. M., Macaluso, M., Mattingly, G. W., Shelton, R. C., Zajecka, J. M., Fu, D. J.
Paywallindividual

Esketamine nasal spray versus quetiapine XR in adults with treatment-resistant depression: a secondary analysis of the ESCAPE-TRD randomized clinical trial

In a secondary analysis of ESCAPE-TRD (n=636), esketamine nasal spray plus an oral antidepressant, dosed according to US prescribing information, produced significantly higher remission rates from week 8 to week 32 and greater, earlier reductions in MADRS scores (from day 8) than quetiapine XR, with fewer discontinuations due to adverse events.

Published
Journal
CNS Spectrums
Authors
McIntyre, R. S., Mattingly, G., Godinov, Y., Buyze, J., Turkoz, I., Cabrera, P., Patel, M., Martinez, L., Himedan, M., Lopena, O.
Open Accessindividual

Antianhedonic Effect of Repeated Ketamine Infusions in Patients With Treatment Resistant Depression

In 42 patients with treatment‑resistant depression, eight adjunctive ketamine infusions produced a statistically significant reduction in anhedonia (SHAPS), and this antianhedonic change mediated ketamine’s antidepressant effect, with one‑week post‑treatment benefits observed only in patients not taking benzodiazepines. These preliminary results require replication in a larger randomised placebo‑controlled trial.

Published
Journal
Frontiers in Psychiatry
Authors
Wilkowska, A., Wiglusz, M. S., Cubała, W. J., Galuszko-Wegielink, M., Wlodarczyk, A.
Open Accessindividual

A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression

In this double‑blind, active placebo‑controlled trial in treatment‑resistant depression, six repeated subanaesthetic ketamine infusions produced greater antidepressant responses and higher remission/response rates than midazolam after four to five infusions and were relatively well tolerated. However, at the primary endpoint (change in MADRS 24 h after the last infusion) six ketamine infusions did not significantly outperform a single ketamine added to midazolam, and differences in time to relapse were nominal but not statistically significant.

Published
Journal
Translational Psychiatry
Authors
Shiroma, P. R., Thuras, P., Wels, J., Albott, C. S., Erbes, C., Tye, S., Lim, K. O.

Quick Facts

Full Name
Inventory of Depressive Symptomatology – Clinician Rated
Domain
Depression
Papers Indexed
7
Score Range
0–84
Interpretation
Lower = better
Unit
points
All Measures